Muneer Ahmed, Blueocean Market Intelligence
Muneer Ahmed, Vice President, Market Insights and Strategy, Blueocean Market Intelligence
Muneer has delivered international projects in market access, competitive intelligence and strategy. With over 15 years of experience, he has planned and collaboratively engaged cross-functional teams, built strong personal networks and influenced all levels. In addition to his scientific background, he thoroughly understands brand value propositions, strategic assessments and lifecycle management.
Dave Alderman, Molekule Consulting
Dave Alderman, President, Molekule Consulting
David Alderman is President of Molekule Consulting (“Molekule”), a global competitive intelligence and management consultancy headquartered in Miami, Florida. Molekule partners with pharmaceutical, biotechnology and medical device companies providing evidence-based solutions and actionable strategic and tactical insights. Aligning intelligence outcomes and focusing results thereby enabling our client partners — blue chip pharmaceutical and biotechnology players — to win in the highly dynamic and competitive biopharmaceutical universe, Molekule supports seminal biopharmaceutical business objectives. We leverage a continuum of tactical and strategic decisions for pharmaceutical, biotechnology and medical device clients via informed, pragmatic and meaningful competitive intelligence & consulting solutions.
David’s core strength is in partnering with biopharmaceutical clients to develop actionable strategies and critical insights driving business development, sustainable growth, overall strategy and transformational gains for Molekule’s client partners.
David is recognized as a Therapy Area Leader (“TAL”) with an in-depth understanding of multiple disease states, current and future market players, and developmental pipeline compounds in multiple markets and therapeutic areas.
David’s efforts have helped pharmaceutical and biotech companies grow revenues, profits and market share in highly competitive and emerging markets, resulting in a high level of client satisfaction and retention.
Cyrus Arman, Amgen
Cyrus Arman, Director of Business Analysis & Information/ Global Head of Competitive Intelligence, Amgen
Cyrus is a LifeSciences business executive, who emphasizes in competitive strategy, and specializing in competitive landscaping, scenario analysis, and risk assessment.
He has recently joined Amgen, where he now leads the global competitive intelligence function; prior to this he was a Principal at Deallus Consulting where he was a regarded as a leader in workshop/wargame designer and facilitation and lead large strategic projects that leveraged CI methodology into meaningful strategy for clients. Cyrus has worked across cardiovascular, oncology, autoimmune, metabolic, and neuroscience disease areas in research as well as generic/biosimilar, medical device and diagnostic platforms in both research and client facing capacities. Through completing these projects, often times involving multi-million dollar BD investments and partnerships in both the Biopharma and Diagnostics sectors, Cyrus has become well known in the industry as a thought leader in how to transform market insights into action which ultimately impacts the bottom-line of the companies he serves.
Sabih Beck, Roche
Sabih Beck, Oncology & Hematology Franchise Lead, Competitive Intelligence, Roche
Sabih Beck is the Global Oncology and Hematology Franchise lead at Roche’s headquarters in Switzerland. He majored in biochemistry and psychology from Lewis and Clark College (Portland, OR) and obtained his MBS from the Keck Graduate Institute (Claremont, CA).
In the current role Sabih supports oncology products’ marketing strategies by providing commercial recommendations with an external and future looking view on the market. Key responsibilities are planning and leading all strategic external research activities in competitive intelligence.
Prior to his current role, Sabih Beck was the Director of Integrated Insights at Novartis Global Headquarters in Switzerland. Core accountabilities included competitive intelligence, market research, business analytics and forecasting in order to ensure a comprehensive external view and identification of key business drivers for the franchise, ensuring a competitive edge.
Sabih Beck has over 10 years of experience in the field of competitive intelligence leading and building the Global CI function and capabilities in both specialty and primary care franchises within Roche and Novartis. Prior to joining Roche and Novartis he worked in competitive intelligence consulting for various pharmaceutical and biotech companies conducting and planning primary CI efforts, training associates on competitive intelligence & counterintelligence and leading wargames.
Ferdinand Belga, Marathon Pharmaceuticals (Invited)
Ferdinand Belga, Director of Marketing, Marathon Pharmaceuticals
Ferdinand Belga is the Director-Marketing and Pipeline Development at Marathon Pharmaceuticals since January 2014. Marathon Pharmaceuticals is Private Equity owned pharmaceuticals manufacturer. Mr. Belga is responsible for strategic development of Marketing Resources, Sales Execution and Pipeline. He is also involved in Leads Marketing, Sales Management and Sales Training across key growth products, building partnerships across Key Customer Stakeholders to augment pipeline and partnering with Patient Advocacy Groups and KOL Development/Management.
Previously, Mr. Belga was the Director- Corporate Acquisitions/ Licensing/ Business Development at Abbott Laboratories from 2013 to 2014 where he held the responsibility for Strategic Global Initiatives for Corporate Growth across Abbott Divisions for Immediate and Long Term Growth across Key Therapeutic Areas and contributed to Abbott’s external pipeline with partnerships, licensing, acquisitions and development. Prior to this role, Mr. Belga ran a Business Unit in Russia (Emerging Market) for 2 years and transformed a flat business to the fastest growing Women’s and Men’s Health business in Russia (per IMS).
From 2008-2010, Mr. Belga was a Commercial Director based in Singapore responsible for the development of the Sales and Marketing for Russia, India, China (Emerging Markets). Mr. Belga has held several positions at Abbott Laboratories where he was recognized as a Launch Expert (with Antibiotics and HUMIRA, Abbvie’s Flagship Product). He is also serving on the advisory board of Elandas. He has also worked with the University of Illinois at Chicago College of Medicine form 1990 to 1994 in Clinical Research. Mr. Belga has experience in corporate and startup ventures in the pharmaceutical industry in the US and International markets. He has an Executive MBA from the Kellogg School of Management (Northwestern University) and graduated from the University of Illinois with a degree in Biology, Pre Medicine.
Archna Bhandari, Expert System
Archna Bhandari, Vice President, Data and Analytics, Expert System
Archna Bhandari is Vice President of Data and Analytics at Expert System. She brings over 15 years of experience in applying emerging technologies in the biomedical domain. A thought leader in new technology implementation, she sits at the intersection of research and innovation, applying her depth of knowledge and engineering experience to achieve breakthrough results. Prior to joining Expert System, Archna played a critical role in evaluating and deploying new information technology, data analytics and visualization, and knowledge management methodologies to help support high profile and complex biomedical portfolio analyses activities for the National Institutes of Health (NIH). More specifically, Archna played a key role in the successful design and deployment of the NIH Research, Condition and Disease Categorization (RCDC) project. RCDC (http://report.nih.gov/rcdc) provides consistent and transparent information to the public and Congress about NIH research in response to the “NIH 2006 Reauthorization bill – Sec.402 B. Electronic coding of grants and activities.” She was responsible for the data, tools, analysis, and reporting aspect of this very large complex knowledge management system, which depends on multiple data sources, myriad stakeholders across NIH, and is a critical enterprise-wide IT system for the world’s largest biomedical research agency. Archna graduated with a degree in Chemical Engineering and holds a Master’s degree in Computer Science.
Chris Bogan, Best Practices, LLC
Chris Bogan, Chief Executive Officer, Best Practices, LLC
Chris Bogan is the Chief Executive Officer and Founder of Best Practices®, LLC, a leader in the field of best practice performance improvement. Based in Chapel Hill, North Carolina, Best Practices®, LLC specializes in providing pharmaceutical, biotechnology and medical device corporations throughout the world with business intelligence, research, benchmarking studies, and consulting services.
Prior to founding Best Practices, LLC, Mr. Bogan was a principal and founding member of The TQM Group, Ltd., a Bostonbased consultancy. Mr. Bogan also spent many years working at various media companies, including Times Mirror Corp., Knight-Ridder Inc., Howard Publications and Cowles Publishing Co. He has contributed articles to many newspapers and magazines, including The Harvard Business Review, Time, Pharmaceutical Executive, PharmaVoice, MedAd News, Planning Review, The Los Angeles Times, The Boston Globe, The Miami Herald, The Chicago Tribune and The Philadelphia Inquirer. Through his work, Mr. Bogan has toured manufacturing and service companies throughout the world.
Mr. Bogan received his MBA with honors from the Harvard Business School and his bachelor’s degree magna cum laude from Amherst College.
Paul Bould, Abbott
Paul Bould, Divisional Vice President, Marketing Intelligence Global Marketing Organization, Abbott
Beau Bush, OZMOSI
Beau Bush, President and Founder, OZMOSI
Beau has more than 15 years of experience developing data-based business and investment strategies, including extensive experience preparing and delivering senior-level summaries and recommendations for global investment and growth strategies. He left his position in Strategy and Portfolio Analysis at Janssen (Johnson & Johnson) in 2013 to start OZMOSI, when he saw the opportunity to engage more directly with an increasingly complex and dynamic healthcare market.
With newly emerging business models and increasing complexity in drug development making it more and more difficult to predict the impact of new products—or decide which products to pursue—Beau envisioned a company that could bring clarity and confidence to the investment decisions that shape tomorrow’s pharmaceutical products.
Beau has a BS in biology from Rutgers University and has worked in several industries, including finance, pharmaceuticals, marine biology, environmental science, and business consulting.
Salvador Carlucci, Atacana Group
Salvador Carlucci, Head of Competitive Intelligence, Atacana Group
Prior to joining Atacana, Salvador worked as Head of Global Competitive Intelligence (CI) for Roche. Prior to that, Salvador worked as Head of Global CI for Novartis.
Over the last decade, his main accountabilities have been building, growing and leading global CI functions. He has lead CI projects across the lifecycle of the product from early development to loss of exclusivity and lead projects at the business unit level. He has supported functions such as development, regulatory, commercial, advocacy, BD&L, legal, IP, Pharma strategy, senior management and the CEO office. Salvador is a global professional with strong cross cultural perspective, having conducted business in 30+ countries, lived in Europe, North America and Latin America, traveled to 60+ countries and speaking four languages
David Chung, Jazz Pharmaceuticals
David Chung, Senior Director, Strategy & Corporate Development, Jazz Pharmaceuticals
Sharlene Cirillo, Churchill Pharmaceuticals, LLC
Sharlene Cirillo, Vice President, Marketing, Churchill Pharmaceuticals, LLC
Ms. Cirillo joined Churchill Pharmaceuticals in 2016 and is responsible for all marketing aspects for their portfolio of cancer products. Churchill is a venture funded pharmaceutical company utilizing proprietary technology to improve the bioavailability and clinical aspects of oral cancer products.
Prior to Churchill, Sharlene was Head of Global Market Access for the oncology portfolio at GSK/Novartis. The portfolio spanned solid tumors, hematology and supportive care as well as early stage development products. While at GSK, she has also led global and US marketing teams including new product launches.
Her broad-based experience includes pharmaceutical management and a variety of roles in clinical development and medical affairs at Johnson and Johnson.
Vishal Dass, WNS
Vishal Dass, Vice President, WNS
Jamie Denison-Pender, Prescient Healthcare Group
Jamie Denison-Pender, CEO, Prescient Healthcare Group
Jamie is CEO Prescient Healthcare Group, a product strategy consultancy that enhances the value of clients’ products, making sure they resonate with customers and stand out from the competition. He’s spent the past 20+ years growing and managing healthcare-focused consultancies. In 2007 he became managing director of a global competitive strategy company and orchestrated the company’s transition from industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient Healthcare Group in 2010 and led a management buyout in 2014. Jamie remains actively involved with our clients, mainly focusing on strategic simulation workshops and mature brand strategies.
Aaron Derdowski, Proactive Worldwide
Aaron Derdowski, Senior Engagement Manager, Proactive Worldwide
Aaron Derdowski is a Senior Engagement Manager at Proactive Worldwide, Inc., a global decision support, research and consulting firm that provides evidence-based strategic intelligence anchored by primary research. He currently leads engagements for a broad set of clients covering life sciences, healthcare, and medical devices.
Aaron came to Proactive in 2013 with over 8 years’ experience in medical writing, science writing & editing, critical scientific review, and university level teaching and lecturing. He has expertise in several therapeutic areas including HIV biology, oncology, respiratory diseases, neurodegeneration, and autoimmune diseases.
Aaron received his Ph.D. in Microbiology & Immunology from Vanderbilt University and has 6 years of postdoctoral experience from Brown University.
Rebecca Derwin, EMD Serono
Rebecca Derwin, Director, EMD Serono
Rebecca Derwin is currently a Director at EMD Serono. Prior to joining EMD in 2013, she worked at Phasic Strategy, Genzyme, The Frankel Group and Wood Mackenzie Life Sciences supporting wargaming, competitive intelligence, qualitative market research, and patient-based forecasting. Rebecca holds a B.S. from Worcester Polytechnic Institute (WPI) and a MPH from Tufts University School of Medicine.
Marcus Droege, Celgene Corporation
Marcus Droege, Ph.D, MBA, Global Head, Knowledge & Strategic Intelligence, Celgene Corporation
Dr. Marcus Droege leads Celgene’s Global Knowledge & Strategic Intelligence efforts. He develops strategies for real-world data assets and analytics and provides decision support for global, complex information and knowledge management initiatives, process implementation, evidence generation planning, and compliant global content sourcing.
Samer Eid, Merck
Samer Eid, Director, Corporate Development, Merck
Samer Eid is Director and Global Competitive Intelligence Lead at Merck. In his current role Dr. Eid leads the Neuroscience and Women’s Health Drug Development and Commercial CI strategy by proactively partnering with Commercial, New Products, BD&L, Clinical Development, and Discovery teams. Dr. Eid key responsibility is to protect and maximize the value of the pipeline and portfolio by generating actionable insight with the ultimate goal of ensuring product/asset differentiation and informed decision making about resource deployment based on sound evidence. Prior to moving into his current role, Dr. Eid assumed several leadership roles at different stages of the Drug Discovery and Development process at Merck. He championed a number of discovery efforts and led several cross-functional teams in the Target Validation, Lead ID, and Lead Opt space for pain and migraine programs. He has significant experience working with external partners leading research collaboration project teams. Dr. Eid gained tremendous experience sitting on early Clinical Development teams and supporting the development (up to Phase II) of compounds for several indications. He earned his Ph.D. from the Swiss Federal Institute of Technology (Zurich, Switzerland), his Masters (DEA) from the Louis Pasteur University (Strasbourg, France) and his bachelor’s degree from the American University of Beirut (Beirut, Lebanon). He was awarded the fellowship for advanced researchers from the Swiss National Science Foundation to complete his joint postdoctoral studies at the Scripps Research Institute and GNF in La Jolla, California. Dr. Eid is multilingual and is a citizen of the US, Switzerland and Lebanon.
Eduardo Fernandez, Exeltis
Eduardo Fernandez, VP of Business Operations and Consumer Brands, Exeltis
Eduardo is currently VP of Business Development and Business Operations at Exeltis USA, Inc. a specialty pharma company focused on Women’s Health and Dermatology. Roles and responsibilities include management of the Consumer Brands business, Commercial Innovation programs, Portfolio management as well as Business Development and M&A.
Prior to joining Exeltis USA in 2012, Eduardo developed is career for over 11 years as Strategy and Business Consultant in Global firms like PricewaterhouseCoopers and Capgemini Consulting. As a Portfolio Expert he focused on helping clients improving their commercial excellence by gaining better market and consumer understanding and adapting its portfolios and operations, as well as supported Digital Transformation programs for large corporations. Eduardo earned in 2001his MEng degree by a leading University in Europe, with its MBA at IESE Business School complemented by a Strategic Marketing executive program at Wharton Business School.
Chris Ficklin, Eli Lilly and Company
Chris Ficklin, Analyst, Strategic Competitive Intelligence, Eli Lilly and Company
Chris Ficklin is an analyst in the Strategic Competitive Intelligence organization at Eli Lilly and Company. For the past 5 years, Chris has provided CI to support aspects of Lilly’s therapeutic portfolio as well as biotechnology efforts and senior executive requests. In addition to these efforts, Chris leads the department initiative to identify and evaluate new tools, technologies and methods to enhance and improve the deliverables of the organization. Prior to joining the CI group, Chris spent the previous 11 years at Lilly as a biologist supporting biomarker, genomics, patient tailoring, and bioinformatics efforts, providing him a diverse array of scientific and technical skills which allow for a deep understanding of the technology needs of the organization.
Omar Gaya, Regeneron Pharmaceuticals
Omar Gaya, Senior Director, Strategic Analysis & Corporate Strategy, Regeneron Pharmaceuticals
Omar Gaya is the founder and head of the Strategic Intelligence team at Regeneron Pharmaceuticals. Over the past ~5 years, Omar and his team have provided in-depth coverage of the competitive environment around Regeneron’s product portfolio, which spans several therapeutic areas.
Prior to joining Regeneron Pharmaceuticals, Omar held roles in competitive intelligence and strategy at Amgen and Gilead Sciences. Omar holds a BS in Bioengineering and a BA in Applied Mathematics from University of California, San Diego and a Masters in Bioscience from the Keck Graduate Institute.
Venu Gopalakrishnan, PTC Therapeutics
Venu Gopalakrishnan, Executive Director, Global Business Analytics, PTC Therapeutics
He has over 15 years of competitive intelligence experience with various pharmaceutical companies Prior to joining PTC Venu led Business analytics function at Nevakar. Venu has led business analytics functions for multiple orphan disease drugs including ONIVYDE® in Oncology at Merrimack pharmaceuticals, GATTEX® & NATPARA® for rare diseases at NPS Pharma. Prior to NPS Venu held various roles of increasing responsibilities in Strategic Planning, Investor Relations, Marketing Research, Business Development and Competitive Intelligence at Valeant Pharmaceuticals.
Sandra Graham-Mason, Eisai
Sandra Graham-Mason, Associate Director, Oncology Marketing, Eisai
Heath Gross, Sedulo Group
Heath Gross, Founder & CEO, Sedulo Group
As founder and Managing Partner, Heath Gross has built Sedulo Group into a world-class provider of competitive intelligence and strategic consulting services. He is a seasoned competitive intelligence professional with over ten years of experience in both primary research and strategy consulting. Heath served as both a Counterintelligence Agent and a source operations specialist for the US Government prior to his civil career in competitive intelligence. He was responsible for leading source operation activities in Eastern Europe, North African and the Middle East.
Michael Hay, Informa Pharma Intelligence
Michael Hay, Head of Intelligence Products, Informa Pharma Intelligence
Michael is the Head of Intelligence Products for Informa Pharma Intelligence, which includes Citeline, Datamonitor, Biomedtracker and Medtrack. Michael came to Informa through the acquisition of Sagient in 2012, where he had been since 2004. Michael has 16 years of financial markets experience, having previously worked as a Manager in Thomson Financial’s Capital Markets Intelligence division. Michael has consulted numerous top tier pharmaceutical companies on strategic decisions as well as worked closely with top healthcare investment firms providing insight on investment and trading decisions. Michael is the co-author of the Nature Biotechnology feature Clinical Development Success Rates for Investigational Drugs. He has also served on the BIO CEO Advisory Board. Michael holds a Bachelor of Science in Finance from the University of Colorado, Boulder (also his home town).
Darien Kadens, Lupin Pharmaceuticals
Darien Kadens, Head of Market Intelligence – Latin America, Lupin Pharmaceuticals
Darien Kadens, Ph.D., MBA is Head of Market Intelligence – Latin America at Lupin, where he provides market intelligence support for business development in the Latin America region. Previously, Dr. Kadens served as Associate Director of Global Commercial Assessments at Forest Laboratories. Before that, he was Senior Director of Market Intelligence at OptumInsight. Prior to that, he was Global Head of Competitive Intelligence for the Novartis OTC business unit.
Ryan Keeling, Diaceutics
Ryan Keeling, COO, Diaceutics
As Chief Operating Officer of Diaceutics, Ryan is responsible for overseeing operations across the company.
Ryan joined Diaceutics in 2009 and has utilised his expertise in commercial, data and pharma strategy to work on multiple diagnostic/therapy launches since then. Ryan is focused on providing strategic advice to our pharma clients that is supported with a strong background in market access and reimbursement.
Maureen Nail, Pfizer
Maureen Nail, Director, Competitive Intelligence, Pfizer
Maureen joined Hospira/Pfizer in April 2015. She leads the global competitive intelligence platform for Pfizer’s Global Established Products (GEP). She is focused on designing and executing a ”fit-for-purpose” intelligence organization that provides tailored offerings to GEP’s business units (SI, SOD, Biosimilars and CM).
Prior to Pfizer, Maureen was a Consultant at Deallus Consulting, where she led many strategic monitoring projects and competitive simulations. Maureen was also full-time onsite at Astellas to support their re-design and implementation of a competitive intelligence function. Prior to Deallus, Maureen was a Consultant at Defined Health, a boutique business development and strategy management consulting firm.
Maureen received a Ph.D. in Cell Biology from the University of Alabama at Birmingham, a MBA in Managing Innovation from Virginia Commonwealth University, and a B.A. in Biology from Kalamazoo College.
Katherine Kim, Pharmacyclics
Katherine Kim, Associate Director, Business Analysis, Pharmacyclics
Chet Kitchen, Merck & Co.
Chet Kitchen, Director, Global Competitive Intelligence, Merck & Co.
Chet Kitchen is a Director in Global Competitive Intelligence at Merck & Co., Inc. leading the franchise-specific CI activities for Merck Vaccines. In this role, Chet provides strategic and tactical competitive intelligence and recommendations to internal clients within the R&D, commercial, manufacturing, and business development functional areas supporting Merck’s vaccines business.
Prior to joining the Competitive Intelligence group in 2011, Chet held roles of increasing responsibility in Clinical Drug Metabolism, Project Management, and Medical Affairs and Policy within Merck. Chet also worked in medical examiner facilities as a Forensic Investigator, Forensic Toxicologist, and Autopsy Technician prior to joining Merck.
Chet has a BA degree in Chemistry from the University of South Florida in Tampa, FL and completed additional study towards a MBA at Holy Family University in Philadelphia, PA.
Kirsten Kliwinski, Patheon
Kirsten Kliwinski, Senior Director, Strategic Business Intelligence, Patheon
Michael Kostelansky, Daiichi Sankyo, Inc.
Michael Kostelansky, Director Market Research, Business Development, Daiichi Sankyo, Inc.
Jacob Lai, Versartis
Jacob Lai, Sr. Director, Market Planning, Versartis
Jacob has more than 10 years of experience in commercial and commercial strategy functions to bring pharmaceutical and biotechnology products to market in specialty markets and orphan diseases. He currently leads market planning at Versartis, an endocrine-focused biopharmaceutical company initially developing novel, long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. Previously, he led global strategic marketing at InterMune, a pulmonology and orphan fibrotic diseases company acquired by Roche; marketing sciences at Pharmacyclics, an oncology company acquired by Abbvie; market planning teams for Avastin®, Rituxan®, and pipeline programs at Genentech; and was a consultant at McKinsey. Jacob has also held R&D and medical affairs roles at Alza, acquired by Johnson & Johnson, and Pharmacia, acquired by Pfizer. He began his career in the pharmaceutical industry at Searle, acquired by Monsanto. Jacob holds a PhD in chemistry from Stanford and BAs from Northwestern.
Bruno Larvol, Larvol
Bruno Larvol, President, Larvol
In founding Larvol, Bruno focused on creating a workforce platform that could deliver customized solutions to the pharmaceutical industry. He has grown the company to over 60 employees and has maintained profitability year over year without external investment. His interest in the intersection between health and data began early in his career at IBM, where he worked as a Senior Consultant in Healthcare Global Services. After his time at IBM, Bruno founded and served as CEO of Cognia, a bioinformatics company. He holds an MBA with distinction from the Kellogg School of Management, an MS in Biotechnology from Northwestern University, and an undergraduate degree with distinction from Sorbonne University in Paris. Bruno lives in San Francisco with his wife Wan, and their son Bradlen.
John Lauria, LCN Consulting, Inc.
John Lauria, Co-Founder, LCN Consulting, Inc.
John Lauria is the co-founder of LCN Consulting, Inc. He has over 20 years of life science industry experience working with experts in multiple therapeutic areas with the majority of that time spent in business intelligence. He has extensive knowledge of all facets of assessing the external ecosystem from his roles as a collector, manager, analyst, and executive. John has a MA in Psychology and completed doctoral coursework at Pace University.
Marc Limacher, INOVIS
Marc Limacher, MBA, Founder and CEO, INOVIS
Marc Limacher started the company in 1992 as a boutique primary CI specialty firm focusing mostly on the IT and life sciences industries.
As a 28-year veteran in the CI and counter-intelligence industry, he has grown INOVIS into a global leader in primary intelligence & strategic consulting services, counting a select group of global Blue Chip companies as loyal clients. The introduction of an expert regulatory intelligence practice as well as the ProACT scenario planning software tool are unique in the industry.
Prior to INOVIS, Marc was Director of Market Intelligence at a leading West Coast institutional investment firm for five years, providing primary intelligence on small-/medium-/large-cap equities via a global employee network of 65 investigative journalists. He also delivers custom CI seminars and is a frequent lecturer on CI and counter-intelligence topics at companies and to academia.
Marc is fluent in 5 languages and enjoys the proximity to the ski slopes from the Lucerne office, the proximity to the Pacific waves from the Palo Alto office, and the proximity to NYC from the Princeton NJ office.
David Linson, Eli Lilly and Company
David Linson, Manager, Strategic Competitive Intelligence, Eli Lilly and Company
David Linson is currently a manager within Eli Lilly’s Strategic Competitive Intelligence organization with 5 years of CI experience. David supports a wide range of Lilly’s portfolio and strategic initiatives including research, regulatory, business development and the C-suite. As an experienced competitive intelligence professional David is focused on understanding the progression of CI organizations, and ensuring that CI is positioned to provide the most impact. Prior to joining the competitive intelligence group David spent 12 years at Lilly as an analytical chemist. His experience driving data based decisions through the entire development chain enables David to set strategic direction while providing tactical short term solutions.
Mark R. Little, Prescient Healthcare Group
Mark R. Little, Ph.D., President & Global Head of Strategic Planning, Prescient Healthcare Group
Mark is currently President & Global Head of Strategic Planning at Prescient Healthcare Group (PHG). Mark is a globally recognized senior executive in competitive intelligence and strategic analysis. For over 20 years he has been a trusted advisor to biopharmaceutical executives. His insights into the marketplace have resulted in hundreds of millions of dollar value to organizations for which he has worked. Prior to joining PHG), Mark built and led the intelligence efforts at GlaxoSmithKline (1993-2002), where he served in various leadership roles in the R&D and Commercial Strategy organizations. Further, Mark built and led the intelligence efforts at Covance, a leading public contract research organization (CRO). As Vice President of Business Intelligence and Market Research, he contributed to decisions leading to significant growth in revenue and profits over ten years to 2012.
Mark is a former President of the Strategic and Competitive Intelligence (SCIP) Association, and has served in various capacities with SCIP, including a five-year stint as a Board Member, three years as Chair, Council of SCIP Fellows, and one year at the Ethics Chair. He was a recipient of the SCIP Fellows award in 2005, and recipient of the SCIP Meritorious in 2014, and is currently a member of the Intelligence Leadership Forum (ILF), and serves on the executive committee of ILF.
Mark has a Ph.D. in Biochemistry from The Ohio State University, a B.S. degree in Chemistry from the University of North Carolina, and held post-doctoral positions at the Department of Pediatrics at UNC, and as a NSF fellow, at the Centre Nationale de la Reserche Scientific in Grenoble, France.
Greta Loring, Alcresta Therapeutics
Greta Loring, Senior Director, Research & New Product Planning, Alcresta Therapeutics
Greta Loring is Senior Director of Research & New Product Planning at Alcresta Therapeutics. Prior to Alcresta, she was Director of Product Development at Enzymatics, where she led the development of enzymes and kits for next generation DNA sequencing and diagnostics. She previously worked on the development of oral enzyme therapeutics at Alnara Pharmaceuticals and Altus Pharmaceuticals. Ms. Loring earned her Ph.D. in biochemistry at the University of Iowa and BS in biochemistry and molecular biology at Juniata College. She was a postdoctoral research associate at Dartmouth Medical School.
Michelle Maddix-Sovero, UCB
Michelle Maddix-Sovero, Ad Interim Head of Foresight, UCB (Invited)
Clive Meanwell, The Medicines Company
Clive Meanwell, CEO, The Medicines Company
Since inception, The Medicines Company has developed and launched multiple new products in cardiovascular, surgical and anti-infective disciplines of hospital medicine. The firm is currently investing aggressively in R&D programs for atherosclerotic cardiovascular disease, anti-bacterial agents against multi-drug resistant infections, and anesthetic/sedative agents with improved safety and economics. The Medicines Company has focused on the theory and practicalities of value-based pricing from the outset – and its product, Angiomax, is the subject of an actively-taught Harvard Business School case study on that subject. The Medicines Company was ranked #2 or #3 in 2014 and 2015 among all publically traded companies across all industries (and the highest among all biotech and pharma companies) by CNBC using their RQ 50 methodology which identifies the most innovative and productive R&D companies in the market. The firm was recently awarded a major contract by the U.S. government for its work on gram-negative multidrug resistance.
BB Biotech invests mainly in leading publically-traded biotech companies, is one of the world’s largest investors, and has performed in the top echelons of global biotechnology funds for more than 20 years.
Previously, Clive held leadership positions with Roche in Switzerland and California focusing on product development, regulatory affairs and marketing. Clive received the 2016 Dr. Sol J. Barer Award for Vision, Innovation and Leadership and has been honored by a range of industry groups. He is a Board member of the Pharmaceutical Research Manufacturers Association (PhRMA) and of the Biotechnology Innovation Organization (BIO).
Before joining the biopharmaceutical sector, Clive trained in medicine and medical oncology, then undertook clinical practice, teaching and oncology research in the Department of Medicine, University of Birmingham, UK.
Nick Mordwinkin, Ultragenyx Pharmaceutical
Nick Mordwinkin, Director, Corporate Strategy, Ultragenyx Pharmaceutical
Nick Mordwinkin is Director of Corporate Strategy at Ultragenyx Pharmaceutical, a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Nick has over 15 years of experience in the biotechnology and pharmaceutical industries, with previous experience as a clinical pharmacist as well as biotechnology equity research. Nick received his B.S. in Biology and Pharm.D. from Nova Southeastern University in 2002 and 2004, respectively, as well as a Ph.D. in Pharmaceutical Science from the University of Southern California School of Pharmacy in 2012. Nick also completed a postdoctoral fellowship at Stanford University in 2014.
Jamie Munro, Clarivate Analytics
Dr. Jamie Munro, Global Practice Leader, Portfolio and Licensing, Clarivate Analytics
Dr. Jamie Munro is Global Practice Leader, Portfolio and Licensing which includes heading CMR a subsidiary of Clarivate. Jamie joined Clarivate from AstraZeneca where he was Head of Portfolio Analytics and Insights and spent eight years in increasingly more senior roles. Jamie has extensive experience in the areas of portfolio management, analytics, benchmarking and more latterly working with Investor Relations on communications and messaging regarding promoting the AZ drug pipeline and portfolio. Earlier experience includes a decade spent in Technology consultancy involving portfolio management systems, web technologies, data mining and reporting. Jamie holds a PhD in finance and gained his tenure in academia before leaving to pursue consultancy.
Marjorie Norman, Pfizer
Marjorie Norman, Director, Worldwide Competitive Intelligence, Pfizer
Marjorie G. Norman is Director, Worldwide Competitive Intelligence for Pfizer, specializing in providing business and competitive intelligence to senior R&D management. Prior to joining Pfizer in 2002, she was Director – Pharmaceutical Practice, at Fuld & Company, a competitive intelligence consulting firm and a Senior Market Research Analyst at Johnson & Johnson Professional. Ms. Norman holds an MBA from the Graduate School of Management at Simmons College and a BA in German and art history from Franklin & Marshall College. She recently returned from a six-month deployment at Population Services International in Nairobi, Kenya, as part of the Pfizer Global Health Fellows program.
Cheri Oban, Genentech
Cheri Oban, Director of CI, Genentech
Angela Panetta, Springer Nature
Angela Panetta, Business Intelligence Product Manager, Springer Nature
Daniel Pascheles, Molekule Consulting
Daniel Pascheles, CEO, Molekule Consulting
Dr. Daniel R. Pascheles is CEO of Molekule Consulting. Pascheles was formerly Head of Global Intelligence at Merck & Co., Inc., which he joined early 2005 from Aventis Inc. where he was Vice President and head of Corporate Competitive Intelligence. He has worked for Aventis and its predecessor company (Hoechst Marion Roussel, Marion Merrell Dow) for 14 years in various positions and locations.
Pascheles studied Pharmacy at the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his Ph.D. in Pharmaceutical Technology from the same university. He has done additional study at the University of Kansas in Lawrence, Kansas.
Pascheles is Past-President and current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG). He is also member of the Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES).
Hari Patel, Genentech
Hari Patel, Group Manager, Genentech (Invited)
Neema Patel, Egalet
Neema Patel, Vice President, Marketing, Egalet
Broad based marketing leader with over 20 years of expertise launching global pharmaceutical brands across diverse therapeutic categories. Have experience in sales, market research, market access, sales training and marketing. Have worked on portfolio strategy from pre-launch planning through loss of exclusivity for healthcare professionals (HCPs) and consumers. Lead and direct large cross functional teams across market access, health outcomes, advocacy, medical, commercial, and finance. Worked on multiple co-promotes with a variety of partners, large and small.
Jonas Pedersén, Deallus Consulting
Jonas Pedersén, CEO and Owner, Deallus Consulting
Jonas Pedersén is the CEO and owner of Deallus Consulting, a lifescience competitive strategy consultancy based out of London with offices in New York, Princeton, Los Angeles and Tokyo. The company works with 20 of the 25 top biopharmaceutical companies advising on commercial and competitive strategy. Jonas is a well-known strategy consultant and CI expert within in the global pharmaceuticals and healthcare sector. Previously, Jonas was the Head and Director of Competitive Intelligence at Amgen Inc. and before that worked for Therapy Area Pain Control within AstraZeneca R&D. Prior to joining the lifescience sector, Jonas was an Assistant Professor and acting Deputy Director at the Department of Musculoskeletal Research, National Institute for Working Life in Sweden. Over his career he has facilitated over 120 strategic workshops such as War Games and Scenario Analysis events and is experienced in all facets of the strategy consulting mix. He has provided advice to many of the world’s leading biopharmaceutical organizations across a range of sectors and is a recognized speaker at Business schools and numerous conventions and forums. Jonas is on the Board of Directors of Isofol Medical AB. Jonas has an Executive MBA from Stockholm School of Economics, a Ph.D. in Neurophysiology and a B.Sc. in Psychology.
Randall Pinchuk, Pacira Pharmaceuticals
Randall Pinchuk, Sr. Director, Strategy and Corporate Development, Pacira Pharmaceuticals
Mark Powzaniuk, Merck
Mark Powzaniuk, Director Corporate Development, Merck
Rafaat Rahmani, Lifescience Dynamics
Rafaat Rahmani, President, Lifescience Dynamics
Rafaat founded Lifescience Dynamics in the summer of 2004. He had a vision of what would make an effective global decision support service, dedicated exclusively to pharmaceutical and biotechnology industries. It would have to be the best in class market research, competitive intelligence and market access, combined with first-rate people and a business model that met their clients’ global insight and foresight requirements. He wanted to deliver a unique service
model that hadn’t been available to the market previously, giving pharmaceutical companies a new and interesting way to manage their market, competitors and payer requirements.
Lifescience Dynamics is headquartered in London with offices in New York. They are privileged to boast an extraordinary worldwide customer base, with teams across the globe supporting firms of all sizes, from top 20 pharmaceutical companies through to smaller niche pharma and biotech firms. Lifescience Dynamics has undertaken research across 86 countries.
Prior to founding Lifescience Dynamics, Rafaat was Vice President of a London-based consulting practice where he was responsible for numerous international projects for top 10 pharmaceutical companies, focusing on all aspects of the clinical development and commercialisation environments at US, European and global levels.
Rafaat holds a Bachelor Business Administration from University of Huston, Texas, USA and an MBA from the Manchester Business School, Manchester, UK.
Alfred Reszka, Merck & Co.
Alfred Reszka, Executive Director and Head, Global Competitive Intelligence, Merck & Co.
Alfred “Al” Reszka is Executive Director & Head, Global Competitive Intelligence at Merck. He and his team include clients from R&D to marketing and manufacturing across a variety of business functions requiring scientific, medical and business intelligence. Roles and responsibilities include strategic benchmarking and strategy development, product surveillance, biosimilars, Diversified Brands, emerging markets,
Osteoporosis and women’s health licensing, business development, and M&A.
Prior to joining the Global Competitive Intelligence group in 2007, Dr. Reszka was Senior Research Fellow in Bone Basic Research at Merck, where he conducted research into the mechanism of action of FOSAMAX and lead the drug discovery effort. He joined Merck in 1997 after conducting postdoctoral research on molecular signal transduction with Nobel Laureates, Edmund Fischer and Edwin Krebs at the University of Washington in Seattle. Dr. Reszka earned his PhD in 1992 at the University of Illinois, Champaign-Urbana.
Anne Marie Robertson, Helsinn Group
Anne Marie Robertson, Vice President Marketing, Helsinn Group
Mary Ann Sarao, Bayer Consumer Health
Mary Ann Sarao, Director, Competitive Intelligence, Bayer Consumer Health
In March 2015, Mary Ann Sarao joined Bayer as Director, Competitive Intelligence. In this role, Mary Ann will be building-out and leading the global competitive intelligence function for Bayer Consumer Health.
Mary Ann has vast experience in the pharmaceutical strategic and competitive intelligence arena, having held positions of increasing responsibility at Pfizer, Merck, J&J, Bristol-Myers Squibb and Royal DSM.
Most recently, Mary Ann led Global Regulatory Intelligence for R&D at Pfizer and Competitive Intelligence for Pfizer Nutrition. Her areas of regional and global support have included consumer products, prescription products, manufacturing, finance, legal, R&D and regulatory.
An innovative and versatile market-intelligence professional, Mary Ann holds a Master’s degree in information research from Rutgers University and a Bachelor’s degree in nursing from Seton Hall University. She also holds an advanced intelligence certification; CIP-II. She is a member of the Intelligence Leadership Forum (ILF) and a current Board member of SCIP – Strategic & Competitive Intelligence Professionals. She was awarded SCIP’s “Most Innovative Thought Leader Award.”
Indra Sethy-Coraci, Boehringer Ingelheim
Indra Sethy-Coraci, Director, Immunology Therapeutic Area Competitive Intelligence, Boehringer Ingelheim
Indra Sethy-Coraci joined Boehringer Ingelheim Pharmaceuticals in 2004 after completing her postdoctoral studies at Columbia University and is now a Principal Analyst in the Competitive Technical Intelligence group supporting autoimmune diseases/immunology. Prior to graduate school, her other industry experience includes approximately five years at Genentech in the departments of Manufacturing, Process Development Sciences and Cardiovascular
Dr. Sethy-Coraci received a B.S. in Chemical Engineering at the University of California, Davis, a PhD in Biochemistry at the Albert Einstein College of Medicine and completed her postdoctoral training in the laboratory of Dr. Samuel C. Silverstein in the department of Physiology and BioPhysics at Columbia University. Her postdoctoral research focused on understanding the role of mononuclear phagocytes in inflammation in Alzheimer’s disease and
Dr. Sethy-Coraci is a member of the New York Academy of Sciences and the Society of Competitive Intelligence Professionals.
Baljit Singh, INOVIS
Baljit Singh, Ph.D., Managing Director and Partner, INOVIS
A recognized expert in competitive and research intelligence in pharma/ biotechnology and generics, he is known for both his analytical insight and his results-oriented approach. Dr. Singh brings with him nearly a decade of client- and agency-side experience, and will also assume leadership of the new INOVIS offices in India as well as overseeing the day-to-day operations of the pharmaceutical division.
Dr. Singh comes to the company from Novartis Pharma AG, where he most recently served as Global Director of Integrated Insights and helped to develop competitive intelligence (CI) functions and processes which are still in effect today. In addition to leading numerous competitor simulations and strategic scenario planning workshops, Dr. Singh spearheaded Novartis’ most comprehensive generics CI tracking program, earning him, as part of a cross functional
team, the highest honors within the global commercial organization.
Previously, Dr. Singh worked as Head of Competitive Intelligence for a major regulatory intelligence firm to help pharmaceutical clients optimize their lifecycle strategies. Dr. Singh studied pharmacy at the Royal Danish School of Pharmacy in Copenhagen, Denmark and received his Ph.D in Pharmaceutics from London School of Pharmacy in 2006. He has also played cricket for the Danish National team for ~10 Years.
Nancy Steele, Pfizer Consumer Healthcare
Nancy Steele, VP External Ventures, Pfizer Consumer Healthcare
Nancy has worked at Pfizer for 30 years in a number of strategic planning and business development roles. Currently Nancy is heading up External Ventures at Pfizer Consumer Healthcare to expand the boundaries of the product portfolio by working with external partners and healthcare start-ups.
Prior to this role, Nancy led strategy and innovation functions in Pfizer Corporate and a number of the Pfizer business units. Earlier in her career, Nancy founded and ran a health services start-up called Pfizer Health Solutions, a subsidiary delivering technology solutions to improve the management of chronic conditions. Prior to Pfizer, Nancy’s experience included clinical research in a psychiatric hospital, marketing in a biomedical start-up, leadership development at IBM, and a ward psychologist in a large mental health facility in Massachusetts.
Karthik Subramanian, Clarivate Analytics
Karthik Subramanian, Lead, Product Management and Strategy for Portfolio and Licensing, Clarivate Analytics
Karthik Subramanian leads the Product Management and Strategy for Portfolio and Licensing segment in Clarivate Analytics which includes flagship products like Cortellis Competitive Intelligence. Karthik works closely with the customers in the pharmaceutical space, formulating strategies and providing products and solutions to help solve their needs. Karthik has extensive experience in the areas of product management, program management and consulting having worked for more than 10 years in the Life Sciences Industry. Karthik holds an MBA in strategy from University of Leeds, UK.
Amanda Wagner, Concert Pharmaceuticals
Amanda Wagner, Vice President, Business Development and Product Strategy, Concert Pharmaceuticals
Ms. Wagner joined Concert in October 2006 and currently serves as Vice President, Business Development and Product Strategy. Her 10-year tenure at Concert has spanned business development, program management, and new product planning. Prior to joining Concert she was in Sales and Marketing for UpToDate®, an online clinical information resource for physicians subsequently acquired by Wolters Kluwer, and was a Senior Research Assistant at McLean Hospital. In 2014, Ms. Wagner received Boston Business Journal’s 40 under 40 award. She holds a BA from Goucher College where she was a Rhodes Scholar nominee, and received her MBA with highest honors from the Simmons School of Management.
Sue Ward, Pfizer
Sue Ward, Senior Director, Worldwide Competitive Intelligence, Pfizer
Sue Ward is currently Senior Director of Worldwide Competitive Intelligence within Pfizer’s Strategy and Portfolio Management group. Previously within Pfizer, Sue led the competitive intelligence team within Information & Knowledge Management. Prior to joining Pfizer, Sue worked in the UK as Associate Director of Competitive Analysis for SmithKline Beecham (SB) (now GSK). Other positions held by Sue within SB included managing a Clinical Information group and the Product Literature Information Service. Sue holds a BSc (Hons) in Biology from University College London and an MSc in Information Science from The City University, London.
Ben Weintraub, inThought Research
Ben Weintraub, Ph.D., President, inThought Research
After completing his training in immunology and biochemistry, Dr. Weintraub began work as a healthcare analyst in 2000, co-founding BiotechTracker, an online tool for investors. In 2004, he became a licensed security analyst with Hibernia Southcoast Capital covering the biotechnology sector, and later performed the same role at Variant Research. In 2006, Dr. Weintraub joined Reuters Insight, providing analysis of drug development and trends in medicine to professional investors. Dr. Weintraub’s team moved Wolters Kluwer to start inThought in January 2009. inThought formed a stand-alone company in May 2014.
Prior to 2000, Dr. Weintraub was senior scientific editor for the biology research journals Cell and Molecular Cell. Dr. Weintraub performed biochemistry and immunology research at Stanford University and at the John Curtin School of Medical Research in Canberra, Australia. He earned his doctorate in Biology from the University of California, San Diego, and a Bachelor of Science in Life Science from the Massachusetts Institute of Technology.
Friederike Wirtz-Brugger, Sanofi
Friederike Wirtz-Brugger, Director, Competitive Intelligence Pharma Products, R&D, Sanofi
Friederike Wirtz-Brugger trained in biomedical technology in Germany and gained a Ph.D. in Neurobiology and Physiology in USA.
She has extensive experience in the pharmaceutical industry both in discovery research and in competitive intelligence functions.
Currently she is heading a global competitive intelligence group, CI Pharma Products, within the Strategy, Science Policy and External Innovation group at Sanofi.